Insmed (INSM) to Release Earnings on Thursday

Insmed (NASDAQ:INSM) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Insmed to post earnings of ($1.17) per share and revenue of $102.31 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Insmed Price Performance

NASDAQ INSM opened at $83.83 on Thursday. The business’s fifty day moving average is $73.87 and its 200 day moving average is $73.45. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $83.89. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market capitalization of $15.00 billion, a PE ratio of -15.10 and a beta of 1.11.

Insider Activity at Insmed

In related news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 13,302 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $80.00, for a total transaction of $1,064,160.00. Following the transaction, the chief financial officer now owns 142,204 shares of the company’s stock, valued at approximately $11,376,320. The trade was a 8.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 495,135 shares of company stock worth $38,409,713. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday. Guggenheim boosted their price objective on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Morgan Stanley boosted their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. boosted their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Finally, Stifel Nicolaus boosted their price objective on Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $90.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.